A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia
- Focus Adverse reactions
- Sponsors InfaCare Pharmaceutical Corporation
- 07 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jan 2014 New trial record